Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07466251) titled 'PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke' on March 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Peking Union Medical College Hospital
Condition:
Acute Ischemic Stroke AIS
Intracranial Atherosclerosis ICAS
Atherosclerotic Plaque
Intervention:
Drug: Rucacuzumab plus standard therapy
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: September 1, 2026
Targe...